HC Wainwright restated their buy rating on shares of GH Research (NASDAQ:GHRS – Free Report) in a research note released on Thursday morning, Benzinga reports. They currently have a $40.00 price objective on the stock. HC Wainwright also issued estimates for GH Research’s Q1 2024 earnings at ($0.20) EPS, Q2 2024 earnings at ($0.21) EPS, […]
18.01.2024 - DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) - GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it recently . Seite 1
DUBLIN, Ireland, Jan. 18, 2024 GH Research PLC , a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced.
Biopharma and resources-pooling company Atai Life Sciences (NASDAQ: ATAI) has invested a total of $50 million in Beckley Psytech Ltd., a U.K.-based clinical-stage biotech advancing short-duration psychedelics for neuropsychiatric conditions.